Printer Friendly

EMD Serono Research and Development Institute signs collaborative research agreement with Massachusetts General Hospital.

M2 PHARMA-September 4, 2014-EMD Serono Research and Development Institute signs collaborative research agreement with Massachusetts General Hospital

(C)2014 M2 COMMUNICATIONS

EMD Serono Research and Development Institute, a subsidiary of Merck, has signed a collaborative research agreement with Massachusetts General Hospital.

It was reported yesterday that the contract has been signed for Systemic Lupus Erythematosus and Lupus Nephritis pathogenesis. Both conditions fall into an area of high unmet medical need, where new therapies are essential, the company said.

According to the contract, EMD Serono Immunology scientists and MGH investigators will collaborate to better characterise and validate the expression of investigative therapeutic targets, pathogenic immune cell types and biomarkers in Systemic Lupus Erythematosus and Lupus Nephritis patients. The transaction will see Massachusetts General Hospital investigators collect bio-specimens to be utilised in several translational research applications, including compound testing and gene expression analysis of target molecules.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 4, 2014
Words:155
Previous Article:Knight Therapeutics signs asset purchase agreement with Orphan Canada.
Next Article:US subsidiary of Lundbeck launches Northera (droxidopa) capsules in US.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters